Slide 1: Evaluation of Anti-uPAR Antibody as a Radiopharmaceutical for Imaging and Treatment of Solid Tumors
Evaluation of Anti-uPAR Antibody as a Radiopharmaceutical for Imaging and Treatment of Solid Tumors 1
Slide 2: Disclaimer, Forward-Looking Statements
Disclaimer, Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,”
Slide 3: EANM Disclosure of Interest Statement
EANM Disclosure of Interest Statement 1) I or one of my co-authors hold a position as an employee, consultant, assessor or advisor for a pharmaceutical, device or biotechnology company. If yes, please specify name/position/company: Yes Raji Nair/Program Management Lead, Andrew Cittadine/COO, Eric K
Slide 4: uPAR - A Promising New Radiopharma Target
uPAR - A Promising New Radiopharma Target Pan-tumor target 10 Involved in tumor growth & metastasis Expressed in aggressive cancers 72-year-old female Metastatic ovarian cancer Primary tumor resected Rarely present in healthy tissue Metastatic 0 disease SUV Urokinase-Plasminogen Activator Receptor (
Slide 5: Aggressive Cancers Express uPAR
Aggressive Cancers Express uPAR Leading Cancer Deaths 2024 % Patients with Cancer Type uPAR Expression Lung and Bronchus Lung and Bronchus Breast1 97% Other 20% Cancers Colon and Rectum Bladder2 89% 9% 55% 8% Pancreas Ovarian3 88% 7% Colorectal Breast Pancreatic4 87% Pancreas Other Cancers Colorecta
Slide 6: MNPR-101: First-in-class uPAR-targeting agent
MNPR-101: First-in-class uPAR-targeting agent MNPR-101 Humanized monoclonal antibody Fab region uPA Strong binding affinity, << nM Not blocked by uPA - uPAR binding uPAR GPI Anchor Cell Surface Molecular model of uPAR in complex with uPA showing uPA and MNPR-101 binding sites. Adapted from Xu 2012 J
Slide 7: Optimizing MNPR-101 Radiopharmaceuticals for the Clinic
Optimizing MNPR-101 Radiopharmaceuticals for the Clinic BEFORE AFTER 10 %ID/g 25 %ID/g 40 %ID/g Tumor Tumor Tumor Antibody-linker ratio Linkers/Chelators Radioprotectants 0 %ID/g 0 %ID/g 0 %ID/g Unoptimized MNPR-101-Zr MNPR-101-Lu MNPR-101-Zr Pancreatic Cancer (MIA PaCa-2) Images @ 6-7 days post inj
Slide 8: Biodistribution supports strong pre-clinical efficacy
Biodistribution supports strong pre-clinical efficacy Pancreatic Cancer Triple Negative Breast Cancer MIA-PaCa2 xenograft mouse model MDA-MB-231 xenograft mouse model 2500 3000 Control Group (No treatment) Control Group(No treatment) * 100 µCi MNPR-101-Lu Group * 2500 100 nCi MNPR-101-Ac Group % of
Slide 9: Appealing Stability and Shelf-life
Appealing Stability and Shelf-life Whole-Body Retention MNPR-101-Zr and MNPR-101-Lu Shelf-life MNPR-101-Lu (2-8°C) MNPR-101-Lu (RT) Before Optimization After Optimization MNPR-101-Zr (2-8°C) 100 100 80 %IA Remaining 60 RCP (%) 95 40 20 0 90 0 3 6 9 12 15 0 2 4 6 8 Days Post-Injection Time (Days) Hig
Slide 10: Human Clinical Data Confirms MNPR-101's Tumor Targeting Ability
Human Clinical Data Confirms MNPR-101’s Tumor Targeting Ability ¹⁸F-fluorodeoxyglucose (FDG) MNPR-101-Zr (72h) 10 0 SUV FDG image acquired 14 days prior to MNPR-101-Zr administration on the same Siemens Biograph Vision Quadra PET/CT System. 10
Slide 11: Favorable Human Radiation Dosimetry Profile
Favorable Human Radiation Dosimetry Profile MNPR-101-Zr Projected MNPR-101-Lu Organ Safety Target Organ Absorbed Dose @43 MBq Dose Coefficient Absorbed Dose @5624 MBq threshold (Gy) (Gy/MBq) (Gy**) (Gy) Liver 7.85 x 10-2 1.63 x 10-3 9.14 30 Kidneys 5.20 x 10-2 1.12 x 10-3 6.30 23 Lungs 3.54 x 10-2 6
Slide 12: Conclusion: uPAR is a Promising Radiopharma Target
Conclusion: uPAR is a Promising Radiopharma Target ▪ Expressed in multiple aggressive cancers ▪ uPAR-targeted MNPR-101-Zr dosimetry analytics show favorable MNPR-101-Lu profile ▪ Radiopharma Imaging and Therapy studies open and enrolling: – MNPR-101-Zr ClinicalTrials.gov: NCT06337084 – MNPR-101-Lu C
Slide 13: Thank you!
Thank you! October 2024 A Monopar Therapeutics